Αρχική World News EMA Recommends Extending Indications for Lisocabtagene Maraleucel World News EMA Recommends Extending Indications for Lisocabtagene Maraleucel Από Ogkologos - 12 Νοεμβρίου, 2025 297 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of adult patients with relapsed or refractory mantle cell lymphoma Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Manipulating an Immune Cell May Make Radiation Therapy More Effective, Study... 12 Φεβρουαρίου, 2024 FDA Granted Accelerated Approval to Belantamab Mafodotin-blmf for Multiple Myeloma 14 Αυγούστου, 2020 Female Breast Cancer is Now the Most Commonly Diagnosed Cancer in... 11 Φεβρουαρίου, 2021 ¿Es seguro el CBD para las personas con cáncer? 19 Αυγούστου, 2021 Φόρτωση περισσοτέρων HOT NEWS New Safety Signal for Use of Ibrutinib in Combination with Rituximab... Dabrafenib–Trametinib Combination Approved for Melanoma, Anaplastic Thyroid Cancer Helping Kids with Cancer Speak for the Supportive Care They Need Women in science: Cancer research pioneers – part 2